sicklecellanemianews4d
SCD patients free of VOEs after treatment with gene-editing therapy
Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...
sicklecellanemianews10d
Why it’s important to celebrate good care when we receive it
Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...
sicklecellanemianews6d
Etavopivat may reduce VOC rate, increase hemoglobin in SCD
Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...
sicklecellanemianews3d
Lessons learned from my most recent sickle cell pain crisis
When a sickle cell pain crisis landed her in the hospital, columnist Mary Shaniqua soon identified the cause: getting two vaccines at once.
sicklecellanemianews11d
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
sicklecellanemianews13d
The difficult reality of dealing with invisible sickle cell complications
Sickle cell disease can manifest as both a visible and invisible illness, depending on the individual and their unique ...
sicklecellanemianews13d
Most SCD patients given Lyfgenia in trials stay free of VOEs: New data
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...